Martingale Asset Management’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCVX
Martingale Asset Management's PCVX Position: Q3 2026 in Review
Martingale Asset Management reduced its Vaxcyte (PCVX) stake by 5.6% in Q3 2026, selling an estimated $123K and leaving 35,442 shares worth $2.02M. The position accounts for 0.05% of the portfolio, ranked #377.
Martingale Asset Management first reported a position in PCVX in Q3 2022 and has held it in 11 quarters since. The position peaked at $2.18M in Q2 2026. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.
- Martingale Asset Management held 35,442 shares of Vaxcyte worth $2.02M as of Q3 2026.
- Martingale Asset Management sold 2,103 Vaxcyte shares in Q3 2026, an estimated $123K.
- Vaxcyte made up 0.05% of Martingale Asset Management's portfolio in Q3 2026, its #377 holding.
- Martingale Asset Management first reported a position in Vaxcyte in Q3 2022 and has held it in 11 quarters since.
- Martingale Asset Management's Vaxcyte position peaked at $2.18M in Q2 2026.
- 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.
Based on Martingale Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.